X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
IPCA Labs Fact Sheet, IPCA Labs Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA Labs Fact Sheet   (IPLB)

Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.

IPCA LABS Price History

Price Rs 587.1
Mkt Cap Rs m 74,091
Vol '000 1.0
P/E X 39.3
P/CF X 19.7
EPS (TTM) Rs 14.9
% ch % 0.4
No. of shares m 126.20
% ch week % 1.2
% ch 1-mth % 3.7
% ch 12-mth % 7.4
52 week H/L Rs 656.0/400.0
(As on Jan 18, 2018 09:37:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

IPCA LABS Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
IPCA LABS EQUITY SHARE DATA
High Rs567907899888643 
Low Rs320541591629503 
Sales per share (Unadj.) Rs222.9260.0249.2230.3254.4 
Earnings per share (Unadj.) Rs25.637.920.17.616.1 
Diluted earnings per shareRs25.637.920.17.616.1 
Cash flow per share (Unadj.) Rs32.546.134.420.629.8 
Dividends per share (Unadj.) Rs4.005.001.0001.00 
Adj. dividends per shareRs4.005.001.000.001.00 
Dividend yield (eoy) %0.90.70.100.2 
Book value per share (Unadj.) Rs123.1155.3174.1179.0194.6 
Adj. book value per shareRs123.1155.3174.1179.0194.6 
Shares outstanding (eoy) m126.20126.20126.20126.20126.20 
Bonus/Rights/Conversions  ESOS---- 
Price / Sales ratio x2.02.83.03.32.3 
Avg P/E ratio x17.319.137.099.535.7 
P/CF ratio (eoy) x13.615.721.736.919.2 
Price / Book Value ratio x3.64.74.34.22.9 
Dividend payout %15.613.25.006.2 
Avg Mkt Cap Rs m55,97091,35694,05795,72372,300 
No. of employees `00010.911.713.013.113.3 
Total wages/salary Rs m3,9184,9805,6516,2566,960 
Avg. sales/employee Rs Th2,578.72,798.52,416.42,213.32,413.5 
Avg. wages/employee Rs Th359.1424.7434.3476.4523.2 
Avg. net profit/employee Rs Th296.6408.1195.473.3152.4 
IPCA LABS INCOME DATA
Net Sales Rs m28,13132,81831,44429,06532,106 
Other income Rs m143223327222226 
Total revenues Rs m28,27433,04031,77129,28732,332 
Gross profit Rs m5,6017,3835,3632,8964,448 
Depreciation Rs m8671,0311,7961,6331,730 
Interest Rs m334269284319241 
Profit before tax Rs m4,5436,3063,6111,1662,703 
Minority Interest Rs m00000 
Prior Period Items Rs m-83-4900 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,2991,5241,019204675 
Profit after tax Rs m3,2364,7852,5429622,028 
Gross profit margin %19.922.517.110.013.9 
Effective tax rate %28.624.228.217.525.0 
Net profit margin %11.514.68.13.36.3 
IPCA LABS BALANCE SHEET DATA
Current assets Rs m13,97216,01419,34816,21917,340 
Current liabilities Rs m6,3377,91512,5179,7009,559 
Net working cap to sales %27.124.721.722.424.2 
Current ratio x2.22.01.51.71.8 
Inventory Days Days9694107105100 
Debtors Days Days5450735657 
Net fixed assets Rs m12,09814,84120,54021,42920,779 
Share capital Rs m252252252252252 
"Free" reserves Rs m15,05119,09821,56422,57824,499 
Net worth Rs m15,53819,59721,96522,59224,553 
Long term debt Rs m3,6622,9404,9874,8433,517 
Total assets Rs m26,97032,10641,24838,91739,595 
Interest coverage x14.624.513.74.712.2 
Debt to equity ratio x0.20.20.20.20.1 
Sales to assets ratio x1.01.00.80.70.8 
Return on assets %13.215.76.93.35.7 
Return on equity %20.824.411.64.38.3 
Return on capital %25.429.214.35.410.5 
Exports to sales %59.260.452.949.248.6 
Imports to sales %15.016.116.715.314.2 
Exports (fob) Rs m16,66719,83616,62414,29915,617 
Imports (cif) Rs m4,2215,2825,2474,4454,571 
Fx inflow Rs m16,76620,04816,74914,29915,617 
Fx outflow Rs m5,8047,2726,9565,8225,828 
Net fx Rs m10,96212,7769,7938,4779,790 
IPCA LABS CASH FLOW
From Operations Rs m 3,888 5,223 4,682 7,087 2,764 
From Investments Rs m -2,599 -3,690 -6,893 -2,183 -1,432 
From Financial Activity Rs m -829 -1,361 2,505 -4,615 -1,591 
Net Cashflow Rs m 460 172 294 288 -259 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 45.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 11.4%
FIIs 25.3%
ADR/GDR 0.0%
Free float 17.4%
Shareholders 36,892
Pledged promoter(s) holding 2.1%
 

Company Information

REGD OFF 48, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067
E-MAIL investors@ipca.com WEB www.ipca.com
TELEPHONE (022) 6647 4444 FAX (022) 2868 6613
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
AUDITOR Natvarlal Vepari & Co.
CHM: Premchand Godha (MD) COMP SEC: Harish P. Kamath (VP - Legal) YEAR OF INC: 1949 BSE CODE: 524494 FV (Rs): 2 DIV YIELD (%): 0.2

More Pharmaceuticals Company Fact Sheets:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON LTD  NOVARTIS  GLENMARK PHARMA  

Compare IPCA LABS With:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON LTD  NOVARTIS  GLENMARK PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex & Nifty Open at Record Highs; Banking & PSU Stocks Rally(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.46% while the Hang Seng is up 0.28%. The Shanghai Composite is trading up by 0.43%.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON IPCA LABS

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS